See more : CVS Group plc (CVSGF) Income Statement Analysis – Financial Results
Complete financial analysis of Galera Therapeutics, Inc. (GRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Lumina Gold Corp. (LUM.V) Income Statement Analysis – Financial Results
- Yiwu Huading Nylon Co.,Ltd. (601113.SS) Income Statement Analysis – Financial Results
- Radix Industries (India) Limited (RADIXIND.BO) Income Statement Analysis – Financial Results
- Sydbank A/S (SYDB.CO) Income Statement Analysis – Financial Results
- Softline Holding PLC (SFTL.IL) Income Statement Analysis – Financial Results
Galera Therapeutics, Inc. (GRTX)
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| Gross Profit | -259.00K | -114.00K | -778.00K | -368.00K | -267.00K | -127.00K | -84.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.12M | 31.01M | 52.42M | 54.85M | 42.33M | 18.66M | 20.59M |
| General & Administrative | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Other Expenses | 0.00 | -11.07M | -7.17M | -3.68M | -1.25M | 0.00 | 0.00 |
| Operating Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Cost & Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Interest Income | 9.82M | 506.00K | 32.00K | 1.17M | 1.82M | 606.00K | 193.00K |
| Interest Expense | 0.00 | 11.57M | 7.19M | 4.88M | 3.03M | 220.00K | 0.00 |
| Depreciation & Amortization | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| EBITDA | -46.69M | -50.61M | -72.56M | -69.01M | -50.69M | -23.52M | -23.82M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.95M | -51.23M | -73.37M | -70.55M | -50.69M | -24.26M | -24.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.13M | -11.07M | -7.17M | -3.68M | -1.25M | 356.00K | 189.00K |
| Income Before Tax | -59.08M | -62.29M | -80.53M | -74.23M | -51.94M | -23.90M | -23.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -70.00K | 7.19M | -16.00K | -9.00K | -223.00K | -360.00K |
| Net Income | -59.08M | -62.22M | -87.73M | -74.22M | -51.93M | -23.68M | -23.55M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| EPS Diluted | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| Weighted Avg Shares Out | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
| Weighted Avg Shares Out (Dil) | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
Are Options Traders Betting on a Big Move in Galera (GRTX) Stock?
Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch
GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today
Galera Therapeutics Stock (GRTX): Why The Price Surged Today
Galera to Present at Two Upcoming Investor Conferences in November
Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Galera Therapeutics plummeted 73% on Tuesday: explore why
Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
Source: https://incomestatements.info
Category: Stock Reports